Share this Article
Low MH, Yeo SJ, Chin PL, Chia SL, Lo NN, Tay KJ
Correspondence: Dr Low Mun Hon, mhlow1@gmail.com
ABSTRACT
INTRODUCTION There is considerable controversy regarding the best method to prevent venous thromboembolism. In 2008, the American College of Chest Physicians (ACCP) published specific guidelines recommending the use of ow-molecular-weight heparin or warfarin, and a target international normalised ratio of 2.0–3.0 for a duration of at least 7–10 days, after elective knee arthroplasties. Many orthopaedic surgeons believe that these recommendations are biased toward reducing deep venous thrombosis (DVT), but neglect the implicated possibility of a higher incidence of wound complications. In order to enable an objective evaluation of the fit of the ACCP recommendations to the needs of our local cohort of patients, we aimed to look at the incidence of DVT in our local population.
METHODS This study was a prospective observational study involving existing local patients in Singapore General Hospital, Singapore, who underwent total knee arthroplasty (TKA) and were on a short course of chemothromboprophylaxis (< 7 days) after the operation. The incidence of DVT in patients was evaluated using DVT imaging 4–6 days after the operation and at one month after the operation.
RESULTS In our study cohort, the prevalence of DVT during the period between postoperative Days 4 and 6 was 12% (11% were distal DVT and 1% was proximal DVT). Only 9% of the patients had DVT one month after the operation. Using chi-square analysis, we found that there was no significant increase in the number of DVT and pulmonary embolism cases 4–6 days and 1 month after the operation (p > 0.05).
CONCLUSION Contrary to the ACCP guidelines, a short course of chemothromboprophylaxis post TKA, lasting no more than 7 days, is safe and adequate in the low-risk Asian population.
Keywords: Asians, deep venous thrombosis, deep venous thrombosis incidence, deep venous thrombosis prophylaxis, total knee arthroplasty
Singapore Med J 2013; 54(10): 560-563; http://dx.doi.org/10.11622/smedj.2013200
REFERENCES
| 1. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 suppl):e278S-325S. | ||||
| 2. Scurr JH, Machin SJ, Bailey-King S, et al. Frequency and prevention of symptomless deep-vein thrombosis in long haul flights: a randomized trial. Lancet 2001; 357:1485-9. http://dx.doi.org/10.1016/S0140-6736(00)04645-6 | ||||
| 3. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 suppl):338S-400S. http://dx.doi.org/10.1378/chest.126.3_suppl.338S | ||||
| 4. Parvizi J, Azzam K, Rothman RH. Deep venous thrombosis prophylaxis for total joint arthroplasty: American Academy of Orthopaedic Surgeons guidelines. J Athroplasty 2008; 23(7 suppl):2-5. http://dx.doi.org/10.1016/j.arth.2008.06.028 | ||||
| 5. Kim YH, Suh JS. Low incidence of deep vein thrombosis after cementless total hip replacement. J Bone Joint Surg Am 1988; 70:878-82. | ||||
| 6. Chin PL, Amin MS, Yang KY, Yeo SJ, Lo NN. Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial. J Orthop Surg (Hong Kong) 2009; 17:1-5. | ||||
| 7. Shen MC, Lin JS, Tsay W. High prevalence of antithrombin III, protein C and protein S deficiency , but no factor V Leiden mutation in venous thrombophilic Chinese patients in Taiwan. Thromb Res 1997; 87:377-85. http://dx.doi.org/10.1016/S0049-3848(97)00141-2 | ||||
| 8. Klatsky AL, Armstrong MA, Poggi J. Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans. Am J Cardiol 2000; 85:1334-7. http://dx.doi.org/10.1016/S0002-9149(00)00766-9 | ||||
| 9. Lin JS, Shen MC, TSay W. The mutation at position 20210 in the 3'-untranslated region of the prothrombin gene is extremely rare in Taiwanese Chinese patients with venous thrombophilia. Throb Haemost 1998; 800:343. | ||||
| 10. Wang CJ, Wang JW, Chen LM, et al. Deep vein thrombosis after total knee arthroplasty. J Formos Med Assoc 2000; 99:848-53. | ||||
| 11. Nathan S, Aleem MA, Thiagarajan P, Das De S. The incidence of proximal deep vein thrombosis folowing total knee arthroplasty in an Asian population: A Doppler ultrasound study. J Orthop Surg (Hong Kong) 2003; 11:184-9. | ||||
| 12. Maynard MJ, Sculco TP, Ghelman B. Progression and regression of deep vein thrombosis after total knee arthroplasty. Clin Orthop Relat Res 1991; 273:125-30. | ||||
| 13. Enyar JJ, Jones RJ, Low-dose warfarin for prevention of symptomatic thromboembolism after orthopaedic surgery. Ann Pharmacolother 2005; 39:1002-7. http://dx.doi.org/10.1345/aph.1E536 | ||||
| 14. Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. J Bone Joint Surg Am 2001; 83-A:900-6. | ||||
| 15. Brookenthal KR, Freedman KB, Lotke PA, Fitzgerald RH, Lonner JH. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty 2001; 16:293-300. http://dx.doi.org/10.1054/arth.2001.21499 | ||||
| 16. Kim YH. The incidence of deep venous thrombosis after cementless and cemented knee replacement. J Bone Joint Surg Br 1990; 72:779-83. | ||||
| 17. Gallus AS, Salzman EW, Hirsh J. Prevention of venous thromboembolism. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Haemostasis and thrombosis: basic principles and clinical practice, 3rd ed. Philadelphia:Lippincott, 1994: 1331-45. | ||||
| 18. Weinmann Ee, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994; 331:1630-41. http://dx.doi.org/10.1056/NEJM199412153312407 | ||||